KCM
ANIP icon

Kennedy Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Kennedy Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5M Buy
295,938
+1,942
+0.7% +$156K 0.43% 59
2026
Q1 		$22.6M Buy
293,996
+80,195
+38% +$6.26M 0.48% 48
2025
Q4 		$16.9M Buy
213,801
+23,414
+12% +$2.03M 0.36% 85
2025
Q3 		$17.4M Sell
190,387
-76,643
-29% -$6.25M 0.39% 65
2025
Q2 		$17.4M Sell
267,030
-19,746
-7% -$1.29M 0.42% 58
2025
Q1 		$19.2M Buy
286,776
+100,501
+54% +$6M 0.46% 44
2024
Q4 		$10.3M Sell
186,275
-2,532
-1% -$145K 0.23% 133
2024
Q3 		$11.3M Sell
188,807
-9,247
-5% -$564K 0.25% 118
2024
Q2 		$12.6M Sell
198,054
-11,972
-6% -$777K 0.27% 112
2024
Q1 		$14.5M Sell
210,026
-18,928
-8% -$1.14M 0.3% 92
2023
Q4 		$12.6M Buy
228,954
+10,882
+5% +$599K 0.28% 108
2023
Q3 		$12.7M Sell
218,072
-91,815
-30% -$5.3M 0.31% 89
2023
Q2 		$16.7M Buy
309,887
+27,266
+10% +$1.21M 0.39% 55
2023
Q1 		$11.2M Sell
282,621
-77,873
-22% -$3.28M 0.33% 79
2022
Q4 		$14.5M Buy
360,494
+18,044
+5% +$678K 0.41% 63
2022
Q3 		$11M Buy
342,450
+180,376
+111% +$6.17M 0.32% 92
2022
Q2 		$4.81M Buy
+162,074
New +$4.68M 0.13% 274
2017
Q3 		– Sell
-57,115
Closed -$2.67M – 735
2017
Q2 		$2.67M Sell
57,115
-25,062
-30% -$1.21M 0.05% 543
2017
Q1 		$4.07M Buy
+82,177
New +$4.61M 0.07% 469
2016
Q2 		– Sell
-15,000
Closed -$505K – 708
2016
Q1 		$505K Buy
+15,000
New +$509K 0.01% 696
2014
Q2 		– Sell
-201,231
Closed -$6.31M – 744
2014
Q1 		$6.31M Buy
201,231
+63,287
+46% +$1.68M 0.12% 324
2013
Q4 		$2.77M Buy
137,944
+27,497
+25% +$357K 0.05% 493
2013
Q3 		$1.08M Buy
+110,447
New +$796K 0.02% 632

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kennedy Capital Management's ANIP Position: Q2 2026 in Review

Kennedy Capital Management increased its ANI Pharmaceuticals (ANIP) stake by 0.66% in Q2 2026, buying an estimated $156K and bringing the position to 295,938 shares worth $24.5M. The position accounts for 0.43% of the portfolio, ranked #59.

Kennedy Capital Management first reported a position in ANIP in Q3 2013 and has held it in 23 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Kennedy Capital Management held 295,938 shares of ANI Pharmaceuticals worth $24.5M as of Q2 2026.
  • Kennedy Capital Management bought 1,942 ANI Pharmaceuticals shares in Q2 2026, an estimated $156K.
  • ANI Pharmaceuticals made up 0.43% of Kennedy Capital Management's portfolio in Q2 2026, its #59 holding.
  • Kennedy Capital Management first reported a position in ANI Pharmaceuticals in Q3 2013 and has held it in 23 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.